Press Releases Keyword Search Year None20202019201820172016201520142013 August 6, 2020 Editas Medicine Announces Second Quarter 2020 Results and Update August 6, 2020 Editas Medicine Regains Full Global Rights to Ocular Medicines July 29, 2020 Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline July 27, 2020 Editas Medicine Appoints Gad Berdugo as Chief Business Officer July 23, 2020 Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update July 7, 2020 Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing June 26, 2020 Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares June 23, 2020 Editas Medicine Announces Pricing of Offering of Common Stock June 23, 2020 Editas Medicine Announces Offering of Common Stock June 12, 2020 Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
July 29, 2020 Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
July 23, 2020 Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update
July 7, 2020 Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing
June 26, 2020 Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares
June 12, 2020 Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease
